Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Camurus, Audiocast, Q3'26

By Inderes11/5/2026, 1:00 PM
Camurus

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Fredrik Tiberg
00:00 - 02:12

Good afternoon, everyone, and welcome to the Camurus presentation of the third quarter 2026. I am Fredrik Tiberg, President and CEO. And with me today are Anders Vadsholt, our Chief Financial Officer, and Richard Jameson, our Chief Commercial Officer. Please note the forward-looking statements which apply to everything we say today. So, moving on to the agenda. I will start with the highlights. Anders will take you through the financials. Richard will cover commercial development, and I will return with an update on the pipeline and our priorities ahead. Before we open up for questions. So let me start with highlights. Q3 was our strongest quarter to date, and the growth was broad-based across the business. Revenues grew 28% to 724 million SEK, driven by record product sales. Operating result rose 40% to 322 million SEK, with a 44% margin. There was no milestone revenue in the quarter, so this is underlying growth, and we ended the quarter with $4.4 billion in cash and no debt. The growth is driven by strong commercial execution throughout our territories. Buvidal grew 26% with gains in every region. Brixadi rose 23%, and in Sweden, we launched Oczyesa for acromegaly. At the same time, we advanced the pipeline. The FDA accepted our CAM2029 NDA with a PDUFA date of December 18th. SORENTO is moving towards the 194 events needed for primary readout. And at the quarter end, or shortly thereafter, we dosed the first patients in our Phase 2b obesity study. So, all in all, strong earnings, a growing commercial base, and a pipeline with significant near-term milestones. We will come back to each of these later in the presentation. First, Anders, on the financials.

Anders Vadsholt
02:13 - 06:04

Thank you, Fredrik. We had a strong third quarter and the numbers speak clearly. Let me focus on what's behind them. The third quarter revenue was 724 million SEK. No milestone revenue was recognized in the quarter. So the increase reflects underlying growth in the commercial business. Over the two-year period, revenue has grown from 480 million in Q3 of 2024 to 560 million in 2025, and now reaching 724 million this quarter, a compound annual growth rate of about 23%. Product sales led growth, reaching a record of 582 million SEK. Buvidal remains the main engine at 574 million, Oczyesa contributed 8 million, and Brixadi royalties from our partner Braeburn reached 137 million SEK. The sales figures will be discussed further in the commercial section. Total operating expenses were 356 million SEK, up 20% from 298 million a year ago. Marketing and distribution costs rose to 153 million from 142 million, reflecting the commercial development of Buvidal and Oczyesa and our expansion into the US. Administrative expenses rose to 53 million from 40 million. R&D costs increased to 142 million from 109 million, mainly due to progress in the SORENTO trial. Costs came below our own phasing plan, which I will discuss in the outlook regarding profitability. The operating result reached 322 million SEK this quarter, up 40%, or 33% at constant exchange rates, from 230 million SEK last year. The operating margin was 44%, up 3 percentage points from last year. Earnings per share after dilution were 4.50 Swedish kronor, compared to 3.23 kronor last year. For the first nine months, total revenues were 1.959 billion SEK and the operating result 783 million. Our cash position at the end of the quarter was 4.4 billion, up from about 4.1 billion at the start of the quarter, reflecting a rise of approximately 285 million SEK and 24% higher than last year. The primary factor was net cash from operating activities, which contributed 329 million before working capital adjustments of 4 million, and we invested 41 million primarily to set up a second manufacturing facility. Importantly, we remain debt-free, giving us real flexibility as we look ahead. Regarding capital allocation for the rest of 2026, our priorities remain unchanged: to finance the business' organic growth, including commercial expansion and pipeline development, while maintaining a strong and flexible balance sheet to support partnerships and business opportunities as they arise. There were no acquisitions or divestitures in the quarter. On the cost side, we have updated the phasing; the additional spend to expand the US activities ahead of the Oczyesa launch is now around 100 million this year, compared with previously 200 million. Second, the buildup is proceeding as planned. As the buildup is aligned with the regulatory timeline, the additional R&D investment is around 50 million, compared with 150 million previously. This is a change in phasing, not in ambition. The spending has moved to 2027. We reaffirm our full-year guidance based on the performance today. We now expect revenues and operating results in the upper half of the range at 2.6 to 2.9 billion SEK and 0.9 to 1.2 billion SEK, respectively. With that, I'll hand over to Richard for the commercial update.

Richard Jameson
06:06 - 09:07

Thanks, Anders. I'll start with Buvidal, where we had another record quarter with sales of 574 million SEK, which was up 26% year-on-year and 10% sequentially in market. Sales were also strong and grew at 26% year on year. So the reported figure reflects real demand. The growth came from every region. Germany continued to penetrate the market, and in the Nordics, growth was driven by expanded access, continued switching from daily treatment, and the transfer of the last patients from other long-acting buprenorphine products. In the UK, growth came mainly from improved access in prisons and in the community. The new funding is reaching patients, but more slowly than we expected. But the direction is right. The transfer of patients from the competing long-acting product in Australia began late in Q3, which has been supported by our medical team, and most patients who want to transfer will have done so by the end of the year. At the end of the quarter, around 81,000 patients were on treatment with Buvidal, which is net 4,000 more than in June, which keeps us on track for our 100,000 patient ambition by the end of 2027. Now moving to the US, where Brixadi continued to grow, royalties were 137 million SEK, up 23% year-on-year and 8% on the second quarter. For the first nine months, royalties are up 35%. Demand continues to grow across treatment settings, and Braeburn has implemented the expansion of both its commercial and its medical organization to reinforce the growth after the period. Brixadi US net sales for 2026 passed $300 million. This triggers the first sales milestone under our license agreement, and a one-time payment of $15 million will be recognized in the fourth quarter. This is a clear marker of the scale. Brixadi has reached scale in the expanding long-acting buprenorphine market, and Brixadi has a clear, differentiated profile. Being the only product offering both weekly and monthly dosing and with comparative data versus daily sublingual buprenorphine, we are now moving across to Oczyesa, where sales were 8 million SEK, up 83% on the second quarter. The majority of which came from Germany, where about 100 patients are now on treatment. This is a share of about 5% of patients on somatostatin receptor ligands, up from 2.5% in June. Feedback from physicians and patients continues to be very positive, and the pace of uptake is set by how often patients visit their clinic when a change of medication is decided. Also, we launched in Sweden in September and the first ten patients are now in treatment. And in the U.K. In the U.K., a large number of formulary applications have been submitted, with decisions expected in Q4, and a few private patients have already started treatment. Finally, Oczyesa was approved in Australia in August and we will decide launch timing there in the context of a possible future GEP-NET indication. And after the quarter, Health Canada approved Oczyesa XR with a planned launch for 2027. And on that, I will now hand back to Fredrik.

Fredrik Tiberg
09:09 - 17:14

Okay. Thank you, Richard. And moving over to the pipeline review. This slide covers CAM2029 across three programs: acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease. The two near-term events are the FDA decision in acromegaly in the US and the SORENTO readouts, of course, in GEP-NET. CAM2029 is approved in the EU, the UK, Australia, and now also Canada under the trade name Oczyesa in Europe and Australia, and Oczyesa XR in Canada. In the US, the FDA accepted our NDA resubmission for Oczyesa in July with a PDUFA date of December 18th. The review is progressing. The complete response letter in June related solely to a GMP inspection at a third-party manufacturing site, and that reinspection has not yet taken place. We are in dialogue with the agency regarding its timing, and we cannot at this moment predict it. That is why we have prepared a contingency plan, and it is now being prepared for submission. We have manufactured CAM2029 at our secondary site in the US, completed stability work, and completed a phase one bioequivalence study in 130 healthy volunteers, which demonstrated bioequivalence between products from the two sites. Additionally, it was completed successfully, I should say. Additionally, the US site recently completed an FDA GMP inspection. The FDA has been informed of the site change. And the information is now with the review team. Adding the site to the application would be considered a major amendment, and under FDA practice, a major amendment can extend the review goal date by three months. We will take that decision in dialogue with the agency and in good time, before the current PDUFA date on the 18th of December, and we will provide information on any updates to the timelines as received. So there is an alternative path to approval. Either way, the aim is the same: a robust, flexible supply chain in good time ahead of the GEP-NET submission, which is the largest opportunity for us in the near and mid-term future. That brings me to two. SORENTO, the largest randomized study of a somatostatin receptor ligand in GEP-NET, enrolled 332 patients in 12 countries, with progression-free survival as the primary endpoint. We expect to reach the target of 194 events around year-end, with topline results in the first quarter of 2027. Those are the expectations. Some 38,000 patients with metastatic GEP-NET are treated with these drugs in the US alone, so a positive outcome opens a substantially larger market opportunity than acromegaly. In polycystic liver disease, new data from the Positano extension studies are due by the end of the year, and we will decide on the next steps together with the SORENTO study and SORENTO results. The next milestones, then, are the FDA decision in acromegaly with 18th December as the current target date and SORENTO top-line data expected in the first quarter of next year. In the early pipeline, CAM2056, our once-monthly semaglutide, has moved into phase two. B, the trial and ethics approvals came in the third quarter and since quarter end. We have dosed the first participants in parallel. Development of a final product design, including the autoinjector pen, is progressing to plan. Our partnership is also on track with Eli Lilly. We are developing long-acting incretins since the option exercise for Amylin agonists in June. We have three programs now running in parallel with Gubra. We are developing a long-acting PTH analog and continuing preparations towards the first clinical trial with the selected lead candidate. So here is the design of the phase two study for CAM2056. We have just started in obesity and overweight. The rationale for this study comes from our Phase 1b study, where monthly CAM2056 showed potential for faster and greater reductions in body weight and glucose than weekly semaglutide with a similar safety and tolerability profile. The Phase 2b study tests higher doses over longer periods of time. 150 participants are randomized 1:1:1 to CAM2056 at 20mg or 10mg, each reached after dose escalation periods, or to placebo. The primary endpoint is relative weight change at week 36. Results are expected in the first half of 2028. We expect the study to show potential for further weight loss with the convenience of once-monthly dosing. So, before going into priorities, I would like to give a note on our commercial leadership. Richard Jameson, here in the room, our Chief Commercial Officer, has decided to retire at the year-end. Richard joined us in 2016 as our first commercial hire and built our commercial organization in Europe, Australia, and the Middle East. Thank you Richard. From everybody at Camurus. We have thoroughly enjoyed our time together, and fortunately, Richard will continue with us as an advisor. From January 1st, Samantha Nickerson takes over as SVP, International Commercial, and member of the Executive Management Team with responsibilities for Europe, Australia, and the rest of the world. Richard Jameson continues to lead our North American business, and Sam has led the UK, which has become one of our largest markets. I look forward to working with her in her new role. Now, over to priorities and a summary. Q3 was a record quarter for Camurus, with strong growth and a 44% margin without one-offs. We reiterate our outlook with results now expected in the upper half of the ranges. This gives us a strong base. Profitable since 2022 and now with 4.4 billion SEK in cash. From here, there are a number of priorities. Commercial execution is one. Strengthening our leadership in opioid dependence and continuing the launch in acromegaly and preparing for the GEP-NET pipeline. With the anticipated FDA approval decision for Oczyesa and the SORENTO readout early next year. And finally, our partnerships and business development, where we continue to evaluate new opportunities that complement our portfolio. We entered this period from a position of strength with a clear path to continued value creation for patients and shareholders. And with that, thank you so much for your attention. And let's open up for questions. And we are now ready for questions.

Operator
17:14 - 17:20

Thanks, Fredrik. The first question is from Romy O'Connor from Kempen. Please go ahead. Romy.

Romy O'Connor
17:22 - 18:07

Great. Hi team. Congrats on the strong quarter and thank you for taking my questions. The first question. So with the 194 events for SORENTO guided to accrue more towards year-end, are you able to comment on how the event growth has tracked relative to your original assumptions? Especially with the original assumptions for the control arm PFS and on the manufacturing side. So given the positive bioequivalence study that you have and the completed GMP inspection at the US sites, are you able to comment on what regulatory steps remain before that can support approval? And has the FDA given you any feedback on whether this pathway is acceptable? Thank you.

Fredrik Tiberg
18:09 - 19:10

Yeah. Good questions. When it comes to the accrual, of course, you know that we have for the past year had the expectation of a Q4 readout for SORENTO. For SORENTO. And I think it has been tracking quite well according to our latest predictions, so to speak. It is always to some degree by chance because these are real events and nobody can predict exactly how patients are going to progress. So, overall, I think we see a high likelihood that we will get the events towards the end of this quarter, but there may also be some events that track into early 2027. I do not have the ability to provide a more precise answer than that.

Unknown 1
19:11 - 19:11

Yeah. Clear.

Fredrik Tiberg
19:12 - 19:43

So when it comes to your second question, we have of course discussed with the agency, both earlier and more recently, the approach we have to secure a second manufacturer for CAM2029. And we have followed those guidance and instructions. And essentially we have everything in place at this point. So it's more about putting the data together and sending the application.

Romy O'Connor
19:46 - 19:47

Thank you so much.

Fredrik Tiberg
19:47 - 19:51

And that is a question of weeks rather than anything else.

Unknown 1
19:52 - 19:53

Yeah.

Operator
19:55 - 19:59

Next question is from Gonzalo from Danske Bank. Please go ahead. Gonzalo.

Gonzalo
20:01 - 20:44

Hi. Thank you for taking my questions. Gonzalo from Danske Bank, and I have a couple of questions. First one on SORENTO. You have previously said that most SORENTO patients have grade two or grade three disease, but do you have any further color you could share on proportions, primarily tumor sites and primary progression of patients enrolled, that would help us to put the timing of events into context against historical studies. And one question also for Anders, you mentioned before that the spending saved in 2026 moves into 2027. How should we think about the implications for next year's margin? And does the approximately 50% margin ambition still stand? Thank you so much.

Fredrik Tiberg
20:46 - 21:52

Yeah. Thank you, Gonzalo. So, when it comes to the baseline characteristics of the SORENTO patients, we have said that a majority of patients are grade two patients. That is about 50%. We also indicated that a small group are grade three. That is a small group and the rest are grade one patients. Compared to previous trials such as Clarinet, we don't have a cap on grade two patients, so we accept Ki-67 above ten and upwards for grade two. And of course, grade three patients by definition. So I think those are the main characteristics when it comes to the primary tumor site. I think you should look upon it as similar to at least the CLARINET study that I think we can and have communicated.

Anders Vadsholt
21:57 - 23:10

Regarding the costs. We have two types of costs. We have the expansion in the US, and those costs are tied to the launch. So that is also tied to increased revenue. And then on the R&D side, we will have a higher level of R&D spend next year because some of the costs will then be incurred in 2026 rather than 2027. So, there will be a higher level of cost on the R&D side than what we had assumed initially, because some of those costs will be incurred next year instead of this year, impacting the profit margin. 50% or now we have reached 44%. That might be a bit higher next quarter. Of course, depending on developments. So I would say that would be the range between 44 and 50. Next year, we will have to invest in the US. But that also generates some revenue on the R&D spend side. Of course, that will increase. So that is the range. I would say that we will be in that range, without being too precise. But we will not easily get up to 50% because we have to invest next year.

Gonzalo
23:13 - 23:14

Perfect. Thank you so much.

Operator
23:19 - 23:22

Next question from Sean Harmer from Jefferies. Please go ahead, Sean.

Sean Harmer
23:25 - 23:45

Hi there. I have three questions, if I may. I am happy to take them one by one. Can you break down the growth between patient volumes and price for Buvidal and give us a sense of how much of the strength should be considered sustainable into full. Q4 and then 2027. That is my first question.

Richard Jameson
23:46 - 24:09

Yeah. So, I think the volume, price, and revenue growth are similar. We have not had any significant price changes this year. So they are aligned. I think growth came from every region we saw this year, with in-market sales growing at the same rate. So right now we're on track for the 100,000 patients at the end of the year. So I think, yes.

Fredrik Tiberg
24:10 - 24:11

It is at the end of next year.

Richard Jameson
24:11 - 24:14

Next year. Yes, of course. Yes, in 2027. All right.

Sean Harmer
24:15 - 24:29

Thank you so much. And then my second question is, when do you expect Braeburn investments behind Brixadi this year to start translating into more visible acceleration in Brixadi revenues.

Fredrik Tiberg
24:30 - 25:32

I think you have. I mean, as we have communicated, they have invested both in the commercial organization and in the medical affairs and medical science liaison structure. If you take the first one, oftentimes when you do a bigger expansion, you will have to do some things on the regional level, you know, redistricting and so forth. And that can initially have a neutral effect. But it usually takes a few quarters before you really see the impact of these types of investments in resources. The same thing goes, of course, for medical advisory and medical affairs. I think you should expect a couple of quarters at least before you start to see impact. And this is more just a general observation rather than information we have from third parties here.

Sean Harmer
25:34 - 25:54

Um, thank you so much. And then just finally, how confident are you that the FDA will reinspect the original EU manufacturing site within the current review cycle? So by the 18th of December, will the US manufacturer actually support approval rather than complicate the review process?

Fredrik Tiberg
25:56 - 26:41

Yeah. I think when it comes to the first question, I can say that I am not confident at this moment. And that is due to the fact that the inspectorate seems to be not communicating that very clearly at this point. So I think I stand by what I said in the presentation. When it comes to the secondary manufacturer and the readiness there, I feel much more confident. So. So that is, I would say, the opposite end of the spectrum. We have had interactions with the agency representatives to support that.

Sean Harmer
26:44 - 26:46

Understood. Thank you so much. That is all my questions.

Operator
26:48 - 26:58

Next question from Matthias. Please go ahead. Matthias. Are you there, Matthias?

Matthias
27:01 - 27:53

Sorry, Matthias. Thanks so much for taking my questions. I have two questions, please. So firstly, with regards to the recently initiated Phase 2 trial with CAM2056 with two different active forms. Why only a placebo control? Why did the study not include an arm with weekly semaglutide as the phase one trial did? And then secondly, perhaps some more insight into what is going on in the US market with regards to the dynamics around switching from other long-acting injectables, but also some of the bottlenecks that have been referenced earlier this year in reports from Camurus regarding physician access and so on. Perhaps a bit more in-depth description of what is going on in Australia. Thanks so much.

Fredrik Tiberg
27:54 - 29:21

Yeah. Thank you. So when it comes to the Phase 2b study, obviously, there is a situation where we had some data that we wanted to add, and that was the long-term data and also the dose-response data. That is what we have fulfilled by the design. We now have a three-armed randomized study. Obviously, we already had the comparative data. Comparative data versus Wegovy. And that is also going to be part of our planned Phase 3 program. So at this point, we felt that that was not necessary. Plus, we don't have the final device ready, as you know. And we have communicated our plans for the phase three studies. And we would like to have that before we do a comparative trial. So we can look into a broader aspect of the treatment than just efficacy, safety, and tolerability. So essentially, we think that this study design fulfills our needs for the moment, and that allows us to proceed and start the phase three study with the amount of information that we considered necessary.

Richard Jameson
29:24 - 30:10

Okay. And I will address the question regarding Australia. So, we started to see the transfer from patients on the other long-acting buprenorphine towards Buvidal at the end of the quarter. I think there is still some way to go and we expect everybody who wants to be transferred over to be by the end of the quarter. As I said, that is progressing. Our medical team is supporting that transfer as well. With the clinics. As for the bottlenecks, you are right; we have talked about that, and we continue to address that capacity issue mostly through our pharmacy injection program, which is expanding all the time. So more and more pharmacies are now delivering Buvidal at the pharmacy level. So, the patient transition creates capacity in the clinic so new patients can start. So that is being addressed as we go forward.

Fredrik Tiberg
30:11 - 30:21

And I think it is also worth commenting that we have seen these transitions being made both in Finland and Sweden and to some degree also in Germany. Germany.

Unknown 1
30:21 - 30:22

Yeah.

Fredrik Tiberg
30:22 - 30:38

From the two long-acting treatments. That has been a very positive experience, at least for the treatment providers and based on the feedback we have seen. So. So we expect this to be uncomplicated.

Matthias
30:41 - 30:42

Thanks so much.

Operator
30:44 - 30:47

Next question is from Philip Weber from Pareto Securities. Go ahead, Philip.

Philip Weber
30:50 - 31:18

Hi. Good afternoon. I have a couple of questions on Buvidal. And maybe also on Australia. So maybe first, you are talking about expecting most, or those who want to switch over to Buvidal in Australia, to do that this quarter. Do you have a sense of how many that is? I believe you have previously mentioned a figure in the range of a few thousand. That is on the competing product right now.

Unknown 1
31:20 - 31:20

Yes.

Richard Jameson
31:20 - 31:41

We have. We mean, obviously Buvidal already had 80% of the share in the Australian market anyway. So it is the 20% remaining. That is somewhere in the region of 3,000 to 4,000 patients, something of that nature. We anticipate the majority of those patients to switch over to Buvidal, as we have seen happen in the other European markets where the competing product was withdrawn.

Philip Weber
31:43 - 32:08

Okay. Good. Thanks. And then just on the phasing of this. Now you are saying most of those are going to switch in Q4. It seems like that would give a clear boost in patient growth, maybe above recent trends. So, is that the right read that Camurus will see kind of a boost, and then should we expect some return to a more normal quarterly pace in 2027 towards that 100,000 target?

Fredrik Tiberg
32:10 - 32:49

I think you can assume also that there will be some. We don't really know the size of that. Some patients will switch over and have their first Buvidal dose in Q1 next year. So it is very difficult to give proportions. But I think, as Richard says, a majority of the patients should complete their treatment with the current product, or at least receive their last dose in December or so and then switch over to Buvidal. So, I think that's a fair estimate.

Philip Weber
32:51 - 33:09

Okay. Thank you. And then just one last question, if I may, regarding the cost guidance. So specifically on the R&D, you are now indicating higher costs in 2027. I just did not understand that. What has caused this shift? It is lower this year and it is pushed to next year.

Anders Vadsholt
33:11 - 33:43

Yeah. A number of milestones for the SORENTO trial will be reached in the first quarter instead of Q4 of this year. That is the majority of the spend. Then there are also some clinical costs that will occur in 2027 instead of 2026. It is nothing unusual. It is more a reflection of how the contracts have been signed. We have, as Fredrik said, initiated the new phase 2b trial. So that, of course, also has a number of costs associated.

Philip Weber
33:45 - 33:48

Okay. Okay. Thanks a lot. That is all for me.

Operator
33:49 - 33:53

Next question is from Christoph from CIB. Please go ahead. Christopher.

Christopher
33:56 - 34:39

Hi there. Christopher. Thank you very much for taking my questions here. I was wondering whether you can give us a view on the potential impact of the US midterm elections on the opioid dependence market; does it make you more optimistic or more cautious? And I guess, are there any hard anecdotes that you have around that? And is it still the case that Buvidal has been the big positive driver versus your past expectations? Uh, that's my first question.

Unknown 1
34:40 - 34:41

Yeah.

Fredrik Tiberg
34:42 - 35:28

It is a very difficult question to answer this early. I mean, there are so many new candidates that have been elected and we don't know yet. But generally speaking, you could say that blue states have perhaps been more positive to treatment than red states traditionally. So. But on the other hand, I would say that the view on opioid dependence treatment or opioid use disorder treatment has been positive across the board, so it is difficult to give a definitive answer. And we have not, I should say, also done a deep dive into this question. So I think I am speaking very loosely here.

Christopher
35:29 - 36:22

Okay. And then, I guess in terms of Europe and Buvidal, you have been growing despite headwinds from the drivers that you originally expected not appearing, which, obviously, you benefited to some degree from the exit of your competitor. Overall, it seems like a sign of a strong business. But I am thinking in particular, has there been progress on German remuneration and why is there a delay in UK disbursement of funds. And then, of course, are you delivering growth in those markets despite that? Is it just primarily the switches, or is it something else?

Fredrik Tiberg
36:24 - 37:33

Well, I can start. I think what we have said is that the growth for Buvidal is broad-based. So, I think that has compensated for the fact that we haven't had the German remuneration change implemented yet. Richard can talk about England, but I think it is broad-based. And when it comes to the UK. Yes, there has been some benefit from the switch from competing products. But what's been very interesting for us to see in the market, for instance, in Scandinavia and Finland, is that we have grown significantly in Finland despite our high market share and we have outgrown the growth from the transitions by far. It is a broad-based growth. It involves many different components, which I think is very positive for the future going forward. Richard, could you shed some more light on this?

Richard Jameson
37:33 - 38:10

Yes. I mean, the growth is broad across countries. I mean, remember the other long-acting buprenorphine was only really present in two countries, a tiny bit in Germany, but mostly in the Nordics. So, it is interesting. We are gaining patients switching from the prison segment and new patients starting treatment who previously avoided it due to the burden of daily medications. So, there is a raft of different dynamics in there, of which the long-acting buprenorphine switch is one. Yes. You are right, but it is a very small part of that because they did not have a high share and were not very visible across Europe.

Fredrik Tiberg
38:11 - 38:32

And I think we should also stress that we are continuing to see a struggle a little bit in the UK. And I think that is just a topic with the political situation changing repeatedly. And then, of course, the general austerity of the UK system.

Christopher
38:35 - 38:50

Got it. So, and then my last question was, are you comfortable with consensus EBIT guidance of 1.7 billion kroner in 2027 and 2.7 billion in 2028? Thank you.

Fredrik Tiberg
38:50 - 39:07

I think we will come back to that question. I think we will address that in Q4, but I find it difficult to comment on this. I understand your perspective. I will get back to the comfort level there. If you don't mind.

Unknown 1
39:08 - 39:09

Thank you.

Operator
39:10 - 39:15

Next question from Georg Tigalonov-Bjerke from ABG. Please go ahead. George.

Georg Tigalonov-Bjerke
39:18 - 40:23

Hi, this is Georg from ABG. Congratulations on the strong quarter and thank you for taking my questions. I have a couple of questions, please. So, firstly, I'm wondering if you saw any pacing or other positive timing effects for Buvidal in Q3. And also wondering if you could elaborate a little on the main positive drivers in Spain and France. And then lastly, now that there are relatively big upcoming changes in Australia and the dynamics, it would be nice to hear if you could say something about the rough split of Australia in your reported MENA plus Oceania sales segment. Are we talking somewhere in the three-fourths or 75% range, or is it significantly more than that? Thank you.

Fredrik Tiberg
40:24 - 40:36

Yeah. I think these are questions for Richard. When it comes to the split. I mean, we should say that Australia is really dominating. So, I don't think we have gone even further than that.

Unknown 1
40:37 - 40:37

Yeah.

Richard Jameson
40:37 - 41:16

In terms of Spain and France specifically, your questions concerned the penetration of the market. They are both markets with a lot of oral use and big opportunities for them. We are making progress in those markets. In Spain, we recently had a change two quarters ago in the position of Buvidal as a first-line treatment rather than use after some of the orals have failed. So that is helping us grow the penetration there. Similarly, in France as well, there is more acceptance of the value that long-acting buprenorphine, Buvidal, brings to the treatment system. More people are understanding that, and more patients are gaining access.

Georg Tigalonov-Bjerke
41:19 - 41:28

And, uh, thank you. And then on the potential phasing or other positive timing factors in Q3, were there any?

Richard Jameson
41:28 - 41:36

No. The in-market demand was aligned with the invoice sales, if you like. So there was no phasing or anything of that nature.

Georg Tigalonov-Bjerke
41:38 - 41:40

Great. Thank you very much. That's all for me.

Operator
41:41 - 41:46

Next question from Damien Chaplin from Stifel. Please go ahead. Your line is open.

Damien Chaplin
41:48 - 42:11

Yes. Hi. Hello. Thank you for taking my question. One follow-up question on CAM2056, please. So looking back at the Phase 1 results, how much of the efficacy advantage observed was driven by the faster dose escalation schedule versus a potential pharmacokinetic benefit from the FluidCrystal formulation?

Fredrik Tiberg
42:14 - 42:52

I did not quite hear that. So the pharmacokinetic benefit, obviously, the impact of the treatment is related to the pharmacokinetics, and CAM2056 does have significantly different pharmacokinetics compared to Wegovy weekly. And that is both in terms of the uptake, the absorption phase, which is significantly slower and a later Tmax, and then together, of course, with the longer duration.

Damien Chaplin
42:55 - 43:07

Okay. Thanks. Maybe a last question. And assuming positive Phase 2 results, would you intend to advance the drug into Phase 3 on your own, or would you seek a partner?

Fredrik Tiberg
43:09 - 43:31

We have not made that decision yet. We have both opportunities, so we are taking one thing at a time. We do believe we can do this as a relatively modest program. I mean, in considering the therapeutic area, of course. So we haven't excluded any possibilities at this point.

Damien Chaplin
43:33 - 43:34

Okay. Thank you very much.

Operator
43:36 - 43:39

There are no more questions at this time. So I hand the word back to you. Fredrik.

Fredrik Tiberg
43:40 - 43:57

Thank you so much, Rayna. I will just finish by saying thank you for attending our call today and looking forward to meeting you. Or coming to the next call in a quarter's time. Thank you so much.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…